Drug intelligence / Profile preview

RSVI-305

Development stage: Preclinical
Lead developer: RosVivo Therapeutics
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

**RSVI-305** is a microRNA (miRNA)-based therapeutic developed by RosVivo Therapeutics, Inc., for the treatment of COVID-19 infections. It employs RNA interference (RNAi) technology to target viral mechanisms, potentially inhibiting SARS-CoV-2 replication or host factors supporting infection. The drug is in preclinical development, with no reported clinical trials or detailed efficacy data available.[3][5]

Beyond the preview

Go deeper on RSVI-305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSVI-305.

Explore the full profile